Holen Sie sich die Stockscreener-App
1.33
0.75%
-0.01
Handel nachbörslich:
1.33
Schlusskurs vom Vortag:
$1.34
Offen:
$1.38
24-Stunden-Volumen:
94,576
Relative Volume:
0.26
Marktkapitalisierung:
$5.54M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-6.78M
KGV:
-0.3722
EPS:
-3.5729
Netto-Cashflow:
$-4.67M
1W Leistung:
-14.74%
1M Leistung:
-24.22%
6M Leistung:
+9.02%
1J Leistung:
+923.86%
1-Tages-Spanne:
$1.31
$1.3899
1-Wochen-Bereich:
$1.31
$1.56
52-Wochen-Spanne:
$0.10
$6.80
Clearmind Medicine Inc Stock (CMND) Company Profile
Firmenname
Clearmind Medicine Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie CMND mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| CMND | 1.33 | 5.54M | 0 | -6.78M | -4.67M | -3.5729 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Clearmind Medicine Inc Aktie (CMND) Neueste Nachrichten
SciSparc Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 - Marketscreener.com
Clearmind Medicine (NASDAQ:CMND) Shares Down 12.3% – What’s Next? - Defense World
Clearmind Medicine Inc [CMND] Revenue clocked in at $0.00 million, down -51.60% YTD: What’s Next? - The DBT News
Clearmind advances trial for alcohol use disorder therapy - Investing.com
Clearmind advances trial for alcohol use disorder therapy By Investing.com - Investing.com Australia
Clearmind Medicine Inc (NASDAQ: CMND): Is Its Value Too High Compared To Others? - Stocks Register
Clearmind Medicine Inc Inc. (CMND) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Examining CMND’s book value per share for the latest quarter - US Post News
Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site - Marketscreener.com
Rail Vision secures $20 million equity deal with Yorkville - Investing.com
SciSparc gains as Clearmind partnership yields 3 new international patent applications - MSN
Clearmind Medicine Completed Type A Meeting with the FDA - GlobeNewswire
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment - Marketscreener.com
Clearmind Medicine appoints new board member - Investing.com
Clearmind, SciSparc slide amid weight-loss study results - MSN
Could Psychedelics End Binge Drinking? A Breakthrough Patent Says Yes - MSN
Clearmind Medicine patents new addiction treatment - Investing.com India
SciSparc Unveils Breakthrough Ibogaine Therapy Patent - TipRanks
Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering - The Bakersfield Californian
SciSparc-Clearmind Medicine Collaboration Announces the - GlobeNewswire
SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy - StockTitan
Contrasting Clearmind Medicine (NASDAQ:CMND) and Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
Clearmind Medicine files patent for PTSD treatment compounds - Investing.com
Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment - Morningstar
SciSparc shares up on patents filed for psychedelic compounds with Clearmind - MSN
SciSparc and Clearmind Innovate Mental Health Treatment - TipRanks
Clearmind Medicine files patent for novel MDMA therapy - Investing.com
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment - Yahoo Finance UK
SciSparc-Clearmind Medicine Collaboration Leads to - GlobeNewswire
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent ... - The Bakersfield Californian
A History of Outperforming Analyst Forecasts and Beating the Odds: Clearmind Medicine Inc (CMND) - SETE News
Financial Metrics Check: Clearmind Medicine Inc (CMND)’s Ratios for Trailing Twelve Months - The Dwinnex
Clearmind and SciSparc file patent for ketamine-based therapy - Investing.com
SciSparc and Clearmind Innovate in Mental Health Therapy - TipRanks
Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment - Morningstar
Clearmind Biomedical Announces FDA Clearance and First U.S. Surgery of the Neuroblade System for Minimally Invasive Neurosurgery - PR Newswire
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Market Exclusive
CMND’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Clearmind receives patent for drug to treat binge behavior - Green Market Report
Clearmind Medicine Inc (CMND) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Clearmind Medicine secures new US patent for binge behavior regulator - Investing.com India
Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment - Yahoo Finance
Clearmind Medicine Inc (CMND) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Is CMND’s price to cash per share ratio a concern for investors? - US Post News
Financial Metrics Unveiled: Clearmind Medicine Inc (CMND)’s Key Ratios in the Spotlight - The Dwinnex
Thinking about buying stock in Brainstorm Cell Therapeutics, Cle - GuruFocus.com
Clearmind, Yissum Apply for International Patent for Psychedelics - MarketWatch
Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders - StockTitan
Clearmind Medicine (NASDAQ:CMND) Stock Price Down 0.8% - Defense World
Why Doximity Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket - Benzinga
Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug - EIN News
Finanzdaten der Clearmind Medicine Inc-Aktie (CMND)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):